Requiem For Cures 2.0: An Idea Whose Time Has Come, But Will Still Have To Wait

The Upton-DeGette legislation wasn’t going to be part of the omnibus bill moving through Congress this week, but its original concepts – creating more clarity on CMS reimbursement – seem as critical as ever.

The FDA and CMS reform legislation known as Cures 2.0 didn’t really have a chance of being included in omnibus package moving through Congress this week, but the fate of the proposal is nevertheless worth reflecting on because of what it says about the pharma industry’s policy needs and political muscle at the moment.

Championed by Reps. Fred Upton (R-MI) and Diana DeGette (D-CO), Cures 2.0 is the follow-up to the 21st Century Cures...